Mylan-Biocon Publish Positive Results for Proposed Trastuzumab Biosimilar

Interchangeability

Earlier this year, we reported that Mylan and Biocon submitted an aBLA for MYL-1401O, a proposed biosimilar to Genentech’s Herceptin® (trastuzumab).  Earlier this week, an article published in the Journal of the American Medical Association (JAMA), titled Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer, A Randomized Clinical Trial, which reports the results of a Mylan/Biocon study of MYL-1401O.  The article concludes that “[a]mong women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome.”

Download PDF

Tagged with 

Comments are closed.